glp-1 and kidney disease Renal effects of receptor agonists tirzepatide in individuals with type 2 diabetes: seeds of a promising future | Endocrine GLP-1s lower BMI, preserve kidney

Table of Contents Jardiance (Empagliflozin) Product Category Diabetes & Heart Failure SGLT2 Inhibitor Generic Name or Biosimilar No Active Ingredient Empagliflozin Prescription Status Prescription-only Targeted Conditions Jardiance is approved to treat the following conditions: Type 2 Diabetes Mellitus (T2DM), to improve glycemic control Heart Failure with Reduced Ejection Fraction (HFrEF), to reduce the risk of cardiovascular death and hospitalization Chronic Kidney Disease (CKD), to slow progression and improve renal outcomes Off-Label Usage Some off-label uses being studied or prescribed include: Heart Failure with Preserved Ejection Fraction (now formally approved) Type 1 Diabetes (investigational

Adequate hydration (minimum 35 ml per kilogram of body weight of filtered water daily) maintains intestinal mucosal secretions that physically flush Candida organisms from gut surfaces and dilute urinary acetaldehyde concentrations

Kuwait University funded Dr Anfal Yousefs PhD studentship

However, the increased GSH levels is dose and time dependent

Circ Cardiovasc Qual Outcomes

When these cells proliferate and stay healthy, hair grows thick and strong